

Table S1. Clinical characteristics of the patients and disease-associated genes

Patient ID	Sex	Age of onset	Clinical feature	Disease gene (phenotype /MIM number)	Mode of inheritance/ Family history	Maximum motor ability	Current motor ability	Spine deformity	Respiratory	Cardiac	CK (U/I)	Edx	Muscle biopsy	Prior negative genetic testing	Management change	
															Investigation /surveillance change	Treatment change
DMD1	M	1-5Y	Difficulty in standing up, proximal muscle weakness, calf muscle pseudohypertrophy	DMD (Duchenne muscular dystrophy/ 310200)	XR /Negative	Independent walking	Independent walking	Lordosis	Mild restrictive lung disease, snoring with ATH	No	18.930	NE	NE	DMD ^b	Muscle biopsy is not necessary.	Steroid
DMD2	M	1-5Y	Proximal muscle weakness	DMD (Duchenne muscular dystrophy/ 310200)	XR /Negative	Independent walking	Wheelchair (loss of ambulation at age 6Y)	No	No	No	9.195	NE	NE	DMD ^b	Muscle biopsy is not necessary.	Steroid
DMD3	M	1-5Y	GDD, proximal muscle weakness, calf muscle pseudohypertrophy	DMD (Duchenne muscular dystrophy/ 310200)	XR /maternal uncle with muscle weakness and death during childhood	Independent walking	Independent walking	Scoliosis	No	No	16.836	NE	Dystrophic change, absence of dystrophin staining	DMD ^b	None	None
DMD4	M	1-5Y	GDD and proximal muscle weakness, calf muscle pseudohypertrophy	DMD (Duchenne muscular dystrophy/ 310200)	XR /Negative	Independent walking	Independent walking	No	No	No	40.000	NE	NE	DMD ^b	Muscle biopsy is not necessary.	Steroid
DMD5	M	1-5Y	Frequent falling, proximal muscle weakness, calf muscle pseudohypertrophy	DMD (Duchenne muscular dystrophy/ 310200)	XR /Negative	Independent walking	Independent walking	Lordosis	No	No	7.708	NE	NE	DMD ^b	Muscle biopsy is not necessary.	Steroid
DMD6	M	1-5Y	pseudohypertrophy calf muscle pseudohypertrophy GDD and proximal muscle weakness	DMD (Duchenne muscular dystrophy/ 310200)	XR /Negative	Independent walking	Wheelchair (loss of ambulation at age 6Y)	No	OSA	No	7.129	NE	Dystrophic change, absence of dystrophin staining	DMD ^b	None	None
DMD7	M	1-5Y	Proximal muscle weakness, calf muscle pseudohypertrophy	DMD (Duchenne muscular dystrophy/ 310200)	XR /Negative	Independent walking	Wheelchair (loss of ambulation at age 12Y)	Scoliosis	OSA, NIV need from age 14	LVNC	5.848	NE	End stage muscle disease, dystrophin staining positive	DMD ^b	None	Steroid
DMD8	M	1-5Y	Walking difficulty, ADHD, autistic, GDD, epilepsy, calf muscle pseudohypertrophy	DMD (Duchenne muscular dystrophy/ 310200)	XR /Negative	Independent walking	Independent walking	Lordosis	No	No	1.0247	NE	NE	DMD ^b	Muscle biopsy is not necessary.	Candidate for Atarulen treatment
MD1	F	1-5Y	Proximal muscle weakness, proximal joint contracture, distal joint hyperlaxity, keratosis pilaris, keloids	COL6A1 (Ullrich congenital muscular dystrophy /254090)	AD /Negative	Independent walking	Wheelchair	Rigid spine	OSA, moderate restrictive lung disease, NIV need from age 14	No EF 69%	623	NE	Myopathic change, SSCD	SMA ^c	Surveillance for respiratory involvement.	None

MD2	M	1-12M	Severe scoliosis, hip dislocation, hypotonia, proximal muscle weakness, distal joint laxity	<i>COL6A1</i> (Ullrich congenital muscular dystrophy /254090)	AD /Negative	Sitting with aid	Sitting with aid	Scoliosis	No	No EF 70%	300	NE	Myopathic change, SSCD		Surveillance for respiratory involvement	None
MD3	M	1-5Y	Proximal muscle weakness, proximal joint contracture, distal joint laxity, keratosis pilaris, keloid	<i>COL6A1</i> (Ullrich congenital muscular dystrophy /254090)	AD /Negative	Independent walking	Independent walking	Scoliosis	Restrictive lung disease	No	815	Myopathic	Myopathic change		Surveillance for respiratory involvement	None
MD4	F	0-1M	Hypotonia recurrent pneumonia, ptosis with ophthalmoplegia	<i>COLQ</i> (congenital myasthenic syndrome/ 603034)	AR /Negative	Sitting alone	Sitting alone	No	OSA	No	50	Repetitive nerve stimulation : normal	Faint alpha-dystroglycan, delta-sarcoglycan		None	Start ephedrine
MD5	M	6-10Y	Progressive proximal muscle weakness, elbow joint contracture, hip joint flexion contracture, wing scapular, rigid spine	<i>FHL1</i> (X-linked myopathy with postural muscle atrophy/ 300696)	vfc	Ccn 2Independent t walking	Independent walking	Scoliosis, Rigid spine	No	No	1.931	Myopathic	Myofibrillar change, desmin aggregation	DMD ^b	Surveillance for cardiac involvement	None
MD6	M	1-12M	GDD, hypotonia with muscle weakness, diffuse abnormal hypersignal of white matter on brain MRI	<i>LAMA2</i> (congenital, merosin deficient muscular dystrophy/ 607855)	AR /Negative	Sitting alone	Sitting alone	Scoliosis	No	No	3.326	Myopathic	Dystrophic change, faint merosin staining	SMA ^c	None	None
MD7	M	1-12M	Delayed motor development, hypotonia with muscle weakness, diffused abnormal hypersignal of white matter on brain MRI,	<i>LAMA2</i> (congenital, merosin deficient muscular dystrophy/ 607855)	AR /Negative	Sitting with aid	Sitting with aid	No	OSA	No EF 66%	1.432	NE	Dystrophic change, absence of merosin staining	SMA ^c	None	None
MD8	F	1-12M	Neck weakness, proximal muscle weakness	<i>LMNA</i> (Emery-Dreifuss muscular dystrophy/ 181350)	AD /Negative	Sit with support, stand holding on	Sit with support, stand holding on	Lordosis	No	No	990	NE	NE	SMA ^c	Muscle biopsy is not necessary. Surveillance for cardiac involvement	None
MD9	F	1-5Y	Toe walking, hypertrophic scar at left knee, gait: lordosis	<i>LMNA</i> (EmeryDreifuss muscular dystrophy/ 181350)	AD /Negative	Independent walking	Dependent walking	Rigid spine, scoliosis, lumbar lordosis	No	NE	194	NE	NE	SMA ^c	Muscle biopsy is not necessary. Surveillance for cardiac involvement	None
MD10	F	1-12M	Delayed motor development, proximal muscle weakness, multiple joint contractures	<i>LMNA</i> (Emery-Dreifuss muscular dystrophy/ 181350)	AD /Negative	Sitting alone	Sitting with aid	Scoliosis	OSA, NIV need from age 6	Atrial fibrillation	756	NE	Dystrophic change	SMA ^c	Surveillance for cardiac involvement	None
MD11	F	1-12M	Delayed motor development, proximal muscle weakness, both ankle	<i>LMNA</i> (Emery-Dreifuss muscular dystrophy/ 181350)	AD /Negative	Independent walking	Independent walking	Lumbar lordosis	No	No	3.266	NE	Dystrophic change	SMA ^c	Surveillance for cardiac involvement	None

contracture, atrophy
of quadriceps muscle

MD12	F	1-5Y	Frequent falls, slow progressive distal muscle weakness of lower limbs	MYH7 (Laing distal myopathy/ 160500)	XR /affected male sibling (MD13), Mother had a traffic accident and was non ambulatory. Motor ability cannot be evaluated.	Independent walking	Independent walking	Scoliosis	Mild restrictive lung disease	No	591	Myopathic	NE	NE	None	None
MD13	M	1-5Y	Frequent falls, progressive distal muscle weakness of lower limbs, severe scoliosis	MYH7 (Laing distal myopathy/ 160500)	XR /Affected female sibling (MD12)	Independent walking	Independent walking	Scoliosis	Restrictive lung disease	No	1.204	Myopathic	Unspecific	NE	None	None
MD14	M	0-1M	Hypotonia and respiratory failure from perinatal period, AMC, delayed motor development, proximal muscle weakness, proximal joint contracture, finger flexion contracture	TTN (Limb-girdle muscular dystrophy/ 608807)	Negative	Independent walking	Independent walking	Rigid spine	OSA	No	86	NE	Dystrophic change, decreased collagen6 staining	NE	Surveillance for cardiac, respiratory involvement, and scoliosis	None
MD15	M	1-5Y	Frequent falling, generalized hypotonia, progressive proximal muscle weakness, areflexia, Gowers' sign positive, waddling gait, toe walking,	No causative variant for muscular dystrophy was found. A homozygous missense variant in the <i>FUS</i> gene known to cause amyotrophic lateral sclerosis, frontotemporal dementia /608030)	Male sibling with proximal muscle weakness, onset 1.5 Y, Serum CPK 958 U/L, muscle pathology was similar to the patient's result, EM showed numerous abnormal mitochondria, deceased at age 9 Y due to respiratory failure	Independent walking	Independent walking	Lordosis	No	No	1.010	Myopathic	Vacuolated muscle fibers with granular eosinophilic and amphophilic materials. COX-negative fibers.	Mitochondrial DNA sequencing for common mutation (A3243G, A8344G, T8993G)	None	None

CM1	F	0-1M	Polyhydramnios, preterm GA 32 weeks, very low birth weight 1300g, congenital hypotonia, with weakness, hyporeflexia, respiratory failure, no liver enlargement, normal liver function test, negative	<i>GBE1</i> (glycogen storage disease type IV/232500)	AR	Bed bound	Deceased at age 2M	No	Require mechanical ventilator	No	231	NE	Glycogen accumulation	Targeted gene panel for neuromuscular disorders	None	None
CM2	M	0-1M	Congenital hypotonia with weakness, areflexia, low APGAR, high arched palate, lung atelectasis	<i>MTM1</i> (<i>myotubular myopathy</i> /310400)	XR /Maternal history of spontaneous abortion	Bed bound	Bed bound	No	Require mechanical ventilator	No	50	NE	NE	SMA ^c	Muscle biopsy is not necessary.	None
CM3	F	1-12M	Delayed motor development, hypotonia, proximal muscle weakness, mild elongated face, high-arched palate, areflexia	<i>NEB</i> (<i>Nemaline myopathy</i> /256030)	AR /Negative	Sitting alone	Sitting alone	No	No	No	78	NE	NE	SMA ^c	Muscle biopsy is not necessary.	None
CM4	M	1-12M	Severe scoliosis, myopathic face, proximal muscle weakness, history of malignant hyperthermia	<i>RYR1</i> <i>biallelic</i> (central core disease /117000)	AR /Negative	Independent walking	Independent walking	Scoliosis	No	No	279	Myopathic	NE	<i>RYR1</i> limited mutation screening ^d	Muscle biopsy is not necessary. Avoidance of volatile anesthetics and depolarizing muscle relaxant	None
CM5	M	1-12M	Feeding difficulties, delayed motor development, myopathic face, high-arched palate, ptosis, ophthalmoplegia, proximal muscle weakness, hyporeflexia	<i>RYR1</i> <i>Biallelic (RYR1-related centronuclear myopathy)</i>	AR /Negative	Independent walking	Independent walking	Lumbar lordosis	No	No	110	NE	Centronuclear	SMA ^c	Avoidance of volatile anesthetics and depolarizing muscle relaxant	None
CM6	M	0-1M	Hypotonia and respiratory impairment from perinatal period, feeding difficulties, myopathic face, high-arched palate, ptosis, ophthalmoplegia, proximal muscle weakness, areflexia	<i>RYR1</i> <i>biallelic (congenital uniform fiber type 1 /117000)</i>	AR /Negative	Independent walking	Independent walking	No	OSA	No	57	Myopathic	Type 1 fiber predominance	SMA ^c	Avoidance of volatile anesthetics and depolarizing muscle relaxant	None

CM7	F	1-12M	Hypotonia, delay motor development, mild long face, high-arched palate	<i>RYR1</i> <i>Monoallelic (RYR1-related congenital myopathy)</i>	AD /Negative	Independent walking	Independent walking	Lumbar lordosis	No	No	54	NE	NE		Muscle biopsy is not necessary. Avoidance of volatile anesthetics and depolarizing muscle relaxant	None
CM8	F	1-5Y	Waddling gait, proximal muscle weakness	<i>TTN</i> <i>biallelic (VUS)</i>	Negative	Independent walking	Independent walking	Lumbar lordosis	No	No	193	NE	NE		None	None
CM9	M	0-1M	Hypotonia, respiratory impairment during perinatal period, proximal muscle weakness, myopathic face, high-arched palate, areflexia	<i>TTN</i> (Limb-girdle muscular dystrophy/608807)	AR /Negative	Independent walking	Independent walking	No	Yes	Yes	57	NE	Centronuclear, fiber type disproportion	SMA ^c <i>RYR1</i> limited mutation screening ^d	None	None

Abbreviations: AD, autosomal dominant; ADHD, attention deficit hyperactive disorder; AMC, arthrogryposis multiplex congenita; AR; autosomal recessive, CK, creatine kinase (normal: < 190 U/L); CM, congenital myopathy; DMD, Duchenne muscular dystrophy; Edx, electrodiagnostic testing; EF, ejection fraction (from echocardiogram); GA, gestational age; F, female; GDD, global developmental delay; LVNC, left ventricular non compaction; M, male; MD, muscular dystrophy; NE, not examined; NIV, non-invasive ventilation; OSA, obstructive sleep apnea; PFT, pulmonary function test; RNS, repetitive nerve stimulation; SSCD, sarcolemma specific collagen deficiency, XR; X-linked recessive

In the patient-ID column, DMD, MD and CM represent patients clinically diagnosed with Duchenne muscular dystrophy, other muscular dystrophies and congenital myopathies, respectively.

^a Describe respiratory and cardiac involvement manifested at the time of testing ^b Multiplex ligation-dependent probe amplification (MLPA) for the *DMD* gene ^c Multiplex ligation-dependent probe amplification (MLPA) of the *SMN1* gene

^d *RYR1* limited mutation screening refers to PCR amplification of exons 10, 11, 39, 40, 41, 43, 44 and 45 of the *RYR1* gene

Sibling relationship

Table S2. Molecular findings

Patient ID	ES	Gene	Reference sequence	Nucleotide change	Zygosity	Parental mutation status	Inheritance	Publication	ACMG classification ^a
DMD1	Singleton	<i>DMD</i>	NM_004006.3	c.515_516dupTC (p.Ile173SerfsTer36)	Hemizygous	Not confirmed	XR	This study	Pathogenic
DMD2	Singleton	<i>DMD</i>	NM_004006.3	c.5932delC (p.Arg1978ValfsTer5)	Hemizygous	Not confirmed	XR	This study	Pathogenic
DMD3	Trio	<i>DMD</i>	NM_004006.3	c.6986delA (p.Lys2329SerfsTer9)	Heterozygous	Maternal allele	XR	[PMID: 26911353]	Pathogenic
DMD4	Singleton	<i>DMD</i>	NM_004006.3	c.8086dupC (p.Leu2696ProfsTer14)	Heterozygous	Not confirmed	XR	[PMID: 31379145]	Pathogenic
DMD5	Singleton	<i>DMD</i>	NM_004006.3	c.8086delC (p.Leu2696TrpfsTer30)	Hemizygous	Not confirmed	XR	[PMID: 8840119]	Pathogenic
DMD6	Singleton	<i>DMD</i>	NM_004006.3	c.9649+5G>T	Heterozygous	Not confirmed	XR	[PMID: 20485447]	Likely pathogenic
DMD7	Trio	<i>DMD</i>	NM_004006.3	c.10097_10099delGAG (p.Gly3366delGAG)	Heterozygous	Maternal allele	XR	[PMID: 19937601]	Likely pathogenic
DMD8	Singleton	<i>DMD</i>	NM_004006.3	c.10108C>T (p.Arg3370Ter)	Hemizygous	Not confirmed	XR	[PMID: 25612904]	Pathogenic
MD1	Trio	<i>COL6A1</i>	NM_001848.2	c.850G>A (p.Gly284Arg)	Heterozygous	<i>De novo</i>	AD	[PMID: 34167565]	Likely pathogenic
MD2	Trio	<i>COL6A1</i>	NM_001848.2	c.868G>A (p.Gly290Arg)	Heterozygous	<i>De novo</i>	AD	[PMID: 30706156]	Pathogenic
MD3	Singleton	<i>COL6A1</i>	NM_001848.2	c.1056+1G>C	Heterozygous	Not confirmed	AD	[PMID: 25749816]	Pathogenic
MD4	Trio	<i>COLQ</i>	NM_005677.3	c.393+1G>A	Homozygous	Paternal and maternal allele	AR	[PMID 32978031]	Pathogenic
MD5	Singleton	<i>FHL1</i>	NM_001159702.2	c.377G>A (p.Cys126Tyr)	Heterozygous	Not confirmed	XR	[PMID: 24928078]	Likely pathogenic
MD6	Trio	<i>LAMA2</i>	NM_000426.4	c.283+1G>C (no other pathogenic variants found)	Heterozygous	Paternal allele	AR	[PMID: 30055037]	Pathogenic
MD7	Singleton	<i>LAMA2</i>	NM_000426.4	c.2718delT (p.Phe906LeufsTer169) c.7452-16T>G	Heterozygous Heterozygous	Not confirmed	AR	This study This study	Pathogenic VUS
MD8	Trio	<i>LMNA</i>	NM_170707.4	c.116A>G (p.Asn39Ser)	Heterozygous	<i>De novo</i>	AD	[PMID: 26098624]	Pathogenic
MD9	Trio	<i>LMNA</i>	NM_170707.4	c.1072G>A (p.Glu358Lys)	Heterozygous	<i>De novo</i>	AD	[PMID: 29764566]	Pathogenic
MD10	Trio	<i>LMNA</i>	NM_170707.4	c.1153_1155delGAG (p.Glu385del)	Heterozygous	<i>De novo</i>	AD	This study	Pathogenic
MD11	Trio	<i>LMNA</i>	NM_170707.4	c.1381-2A>C	Heterozygous	<i>De novo</i>	AD	This study	Pathogenic
MD12	Trio	<i>MYH7^b</i>	NM_000257.3	c.4807G>C (p.Ala1603Pro)	Heterozygous	Maternal allele	AD	[PMID: 29660325]	Likely pathogenic
MD13	Trio	<i>MYH7^b</i>	NM_000257.3	c.4807G>C (p.Ala1603Pro)	Heterozygous	Maternal allele	AD	[PMID: 29660325]	Likely pathogenic
MD14	Trio	<i>TTN</i>	NM_001267550.2	c.38876-2A>C	Compound	Paternal allele	AR	This study	Pathogenic
MD15	Trio	<i>FUS</i>	NM_004960.2	c.2254C>A (p.Arg752Ser) c.616G>A (Gly206Ser)	Heterozygous Homozygous	Maternal allele Paternal and maternal allele	AR	This study [PMID: 20668259]	VUS Likely pathogenic (Not etiologic)
CM1	Trio	<i>GBE1</i>	NM_000158.4	c.1561A>T (p.Lys521Ter) c.1496T>A (p.Met499Lys)	Compound Heterozygous	Paternal allele Maternal allele	AR	This study This study	Pathogenic Likely pathogenic
CM2	Singleton	<i>MTM1</i>	NM_000252.3	c.414_421dupGAGATACG (p.Alal41GlyfsTer17)	Hemizygous	Not confirmed	XR	This study	Likely pathogenic
CM3	Trio	<i>NEB</i>	NM_001164508.2	c.10612C>T (p.Arg3538Ter) c.23967_23970delACCT (p.Pro7990SerfsTer154)	Compound Heterozygous	Paternal allele Maternal allele	AR	[PMID: 27104957] This study	Pathogenic Pathogenic

CM4	Trio	<i>RYR1</i>	NM_000540.3	c.487C>T (p.Arg163Cys) c.15089G>A (p.Arg5030His)	Compound Heterozygous	Paternal allele Maternal allele	AR	[PMID: 27586648] This study	Pathogenic Likely pathogenic
CM5	Trio	<i>RYR1</i>	NM_000540.3	c.11715G>C (p.Gln3905His) c.9611C>T (p.Ala3204Val)	Compound Heterozygous	Paternal allele Maternal allele	AR	This study [PMID: 28818389]	Likely pathogenic Likely pathogenic
CM6	Trio	<i>RYR1</i>	NM_000540.3	c.11314C>T (p.Arg3772Trp) c.10347+1G>A	Compound Heterozygous	Paternal allele Maternal allele	AR	[PMID: 24091937] [PMID: 25957634]	Pathogenic Pathogenic
CM7	Trio	<i>RYR1</i>	NM_000540.3	c.14558C>T (p.Thr4853Ile)	Heterozygous	<i>De novo</i>	AD	[PMID: 23394784]	Pathogenic
CM8	Trio	<i>TTN</i>	NM_001267550.2	c.3926C>T (p.Thr1309Ile) c.28856T>C (p.Ile9619Thr)	Compound Heterozygous	Paternal allele Maternal allele	AR	This study This study	VUS VUS
CM9	Trio	<i>TTN</i>	NM_001267550.2	c.39109G>T (p.Glu13037Ter) c.53348T>C (p.Leu17783Pro)	Compound Heterozygous	Paternal allele Maternal allele	AR	This study This study	Pathogenic VUS

Abbreviations: AD; autosomal dominant, AR; autosomal recessive, VUS; variant of uncertain significance, ES; exome sequencing, XR;
X-linked recessive

^a According to the American College of Medical Genetics and Genomics interpretation guidelines [PMID: 25741868]

^b Sibling relationship

In the patient-ID column, DMD, MD and CM represent patients clinically diagnosed with Duchenne muscular dystrophy, other muscular dystrophies and congenital myopathies, respectively.

Table S3. Characteristics of the 18 novel variants

Gene	Reference sequence	Nucleotide change	SIFT	Polyphen-2	M-CAP	Mutation Taster	CADD score	dbSNP	gnomAD allele frequency	ACMG classification ^a	ClinVar Submitter Accession
<i>DMD</i>	NM_004006.3	c.515_516dupTC (p.Ile173SerfsTer36)	NA	NA	NA	Disease-causing	32	-	-	Pathogenic	SCV002546536
<i>DMD</i>	NM_004006.3	c.5932delC (p.Arg1978ValfsTer5)	NA	NA	NA	Disease-causing	34	-	-	Pathogenic	SCV002546547
<i>GBE1</i>	NM_000158.4	c.1561A>T (p.Lys521Ter)	NA	NA	NA	Disease-causing	42	rs773775991	0.0000041	Pathogenic	SCV002546548
<i>GBE1</i>	NM_000158.4	c.1496T>A (p.Met499Lys)	Damaging	Probably damaging	Damaging	Disease-causing	26.8	-	-	Likely pathogenic	SCV002546549
<i>LAMA2</i>	NM_000426.4	c.2718delT (p.Phe906LeufsTer169)	NA	NA	NA	Disease-causing	33	-	-	Pathogenic	SCV002546551
<i>LAMA2</i>	NM_000426.4	c.7452-16T>G	NA	NA	NA	Polymorphism	24	-	-	VUS	SCV002546552
<i>LMNA</i>	NM_170707.4	c.1153_1155delGAG (p.Glu385del)	NA	NA	NA	Disease-causing	22.5	rs1553265761	-	Pathogenic	SCV002546553
<i>LMNA</i>	NM_170707.4	c.1381-2A>C	NA	NA	NA	Disease-causing	35	-	-	Pathogenic	SCV002546554
<i>MTM1</i>	NM_000252.3	c.414_421dupGAGATACG (p.Ala141GlyfsTer17)	-	-	-	Disease-causing	23.8	-	-	Likely pathogenic	SCV002546537
<i>NEB</i>	NM_001164508.2	c.23967_23970delACCT (p.Pro7990SerfsTer154)	NA	NA	NA	Disease-causing	38	rs756384471	-	Pathogenic	SCV002546538
<i>RYR1</i>	NM_000540.3	c.15089G>A (p.Arg5030His)	Damaging	Probably damaging	Damaging	Disease-causing	32	rs747155223	0.0000517	Likely pathogenic	SCV002546539
<i>RYR1</i>	NM_000540.3	c.11715G>C (p.Gln3905His)	Damaging	Probably damaging	Damaging	Disease-causing	24.2	-	-	Likely pathogenic	SCV002546540
<i>TTN</i>	NM_001267550.2	c.38876-2A>C	NA	NA	NA	Disease-causing	33	rs1185989004	0.000021	Pathogenic	SCV002546541
<i>TTN</i>	NM_001267550.2	c.2254C>A (p.Arg752Ser)	Damaging	Possibly damaging	Damaging	Polymorphism	22.3	-	-	VUS	SCV002546542
<i>TTN</i>	NM_001267550.2	c.3926C>T (p.Thr1309Ile)	Tolerated	Probably damaging	Damaging	Disease-causing	22.6	-	-	VUS	SCV002546543
<i>TTN</i>	NM_001267550.2	c.28856T>C (p.Ile9619Thr)	Tolerated	Possibly damaging	Damaging	Disease-causing	22.7	rs530257812	0.00000401	VUS	SCV002546544
<i>TTN</i>	NM_001267550.2	c.39109G>T (p.Glu13037Ter)	NA	NA	NA	Disease-causing	58	-	-	Pathogenic	SCV002546545
<i>TTN</i>	NM_001267550.2	c.53348T>C (p.Leu17783Pro)	Damaging	Probably damaging	Damaging	Disease-causing	23.5	rs777712545	0.00000403	VUS	SCV002546546

SIFT, sorting intolerant from tolerant (<http://sift.jcvi.org/>); *Polyphen-2*, prediction of functional effects of human SNPs (<http://genetics.bwh.harvard.edu/pph2/>); *M-CAP*, Mendelian clinically applicable pathogenicity score (<http://bejerano.stanford.edu/mcap/>); *MutationTaser* (<https://www.mutationtaster.org/>); *CADD*, combined annotation dependent depletion (<https://cadd.gs.washington.edu/>; recommended pathogenicity threshold >20); *dbSNP* (<https://www.ncbi.nlm.nih.gov/projects/SNP/>); *gnomAD*, <https://gnomad.broadinstitute.org/> NA, not applicable According to the American College of Medical Genetics and Genomics interpretation guidelines